













Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infarction (NSTEMI) Registry

Ramesh Nadarajah ^{1,2,3,*}, Peter Ludman ⁴, Yolande Appelman ⁵,
Salvatore Brugaletta ^{6,7}, Andrzej Budaj ⁸, Hector Bueno ^{9,10,11},
Kurt Huber ^{12,13}, Vijay Kunadian ^{14,15}, Sergio Leonardi ^{16,17},
Maddalena Lettino ¹⁸, Dejan Milasinovic ¹⁹ and Chris P. Gale ^{1,2,3}, on behalf of
the NSTEMI Investigators

¹Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK; ²Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK; ³Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK; ⁴Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; ⁵Department of Cardiology, Amsterdam UMC-Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands; ⁶Hospital Clinic de Barcelona, Barcelona, Spain; ⁷Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ⁸Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland; ⁹Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; ¹⁰Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; ¹¹Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; ¹²3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), Vienna, Austria; ¹³Medical Faculty, Sigmund Freud University, Vienna, Austria; ¹⁴Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; ¹⁵Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ¹⁶University of Pavia, Pavia, Italy; ¹⁷Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy; ¹⁸Cardio-Thoracic and Vascular Department, San Gerardo Hospital, ASST-Monza, Monza, Italy; and ¹⁹Department of Cardiology, University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Received 7 October 2022; accepted 11 October 2022; online publish-ahead-of-print 19 October 2022

Aims

The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation.

Methods and results

Consecutively hospitalised adult NSTEMI patients ($n = 3620$) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (in-hospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin.

Conclusion

The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality.

Keywords

NSTEMI • Prospective • Observational • Non-interventional • EORP • Registry

† The NSTEMI Investigator Group is in the Appendix.

* Corresponding author: Ramesh Nadarajah. British Heart Foundation Clinical Research Fellow, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, 6 Clarendon Way, Leeds, UK LS2 9DA. Tel: +44 (0) 113 343 3241; Email: r.nadarajah@leeds.ac.uk Twitter @Dr_R_Nadarajah

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Introduction

Non-ST-segment elevation myocardial infarction (NSTEMI) is a leading cause of emergency hospitalisation across Europe.¹ For example, it accounts for over 50 000 admissions to hospitals each year in the National Health Service of England and Wales.² Long-term mortality rates for patients hospitalised for NSTEMI are high,³ and the incidence of NSTEMI is increasing across many countries as populations age, and become more comorbid.⁴

Despite substantial improvements in the treatment of NSTEMI, the burden and variation of NSTEMI care and outcomes persist.^{5–7} Clinical outcomes from NSTEMI may be improved through adherence to evidence-based care for NSTEMI.^{8,9} However, between and within European country variation in the delivery and outcomes from NSTEMI suggest that the potential to reduce the burden of cardiovascular disease has not been realised.^{1,8–10} Measuring recognised standards of care is a mechanism by which geographic variation in the use of guideline-indicated treatments for NSTEMI may be addressed and, therefore, cardiovascular outcomes improved.^{11–13}

Following the addition of standardised quality indicators in 2016 to the European Society of Cardiology (ESC) guidelines for the care of patients presenting for NSTEMI from 2015, we had the opportunity to measure the quality of care we provide in the context of NSTEMI.^{14,15} External validation studies have suggested greater attainment of the ESC standards of NSTEMI care is associated with better clinical outcomes.^{16,17} We therefore designed and implemented the EORP NSTEMI registry to identify patterns in NSTEMI care and outcomes across the entire spectrum of patients admitted with NSTEMI in the heterogeneous context of ESC countries.

Aim of the EURObservational Research Programme Non-ST-segment elevation myocardial infarction registry

The aim of the EORP NSTEMI registry is to collect individual patient data for NSTEMI to foster the improvement of clinical outcomes of patients hospitalised for NSTEMI through the identification and reporting of contemporary delivery of guideline-recommended care.

Specifically variation in care by country-income classification, hospital classification, age, sex, diabetic status, chronic kidney disease presence and severity, and risk scores will be investigated.

Quality of care interventions

Using an electronic case report form (eCRF), individual patient data were collected across guideline-recommended NSTEMI interventions. Since the EORP NSTEMI Registry aims to capture real-world NSTEMI management patterns as undertaken in routine clinical practice, local NSTEMI evaluation, management and/or treatment management strategies were not pre-specified by the study protocol.

Setting

The EORP NSTEMI registry is an international prospective, multi-centre, and observational study of patients presenting to hospitals for NSTEMI. All the ESC country members through the 56 National Cardiac Societies and 43 affiliated countries (as there were at time of design of the registry) were invited to participate.

Participating centres were appointed by the respective national coordinator. National coordinators in conjunction with local centres, or participating centres, managed the approvals of national or regional ethics committees, or Institutional Review Boards, according to local regulations.

Centres were chosen in an attempt to allow representation of each category of hospital in proportion to the distribution of the different types of acute centres in the individual country, and to, as far as possible, respect geographical criteria within each country.

Population and consent

The overall patient enrolment period in the study spanned from 11 March 2019 to 6 March 2021, and each centre was limited to two consecutive weeks within the study enrolment period. Participating centres were requested to enrol all consecutive eligible adult patients admitted with a final diagnosis of NSTEMI; that is, patients with Universal Definition acute myocardial infarction, type 1 myocardial infarction, and who did not have persistent ST segment elevation (Table 1).^{15,18} All participating patients received detailed written

Table 1 Definitions used for inclusion of adult patients in the EORP NSTEMI registry

The Universal Definition of acute myocardial infarction is:

A combination of the detection of an increase and/or decrease of a cardiac biomarker, preferably high-sensitivity cardiac troponin, with at least one value above the 99th percentile of the upper reference limit and at least one of the following:

- (1) Symptoms of ischaemia.
- (2) New or presumed new significant ST-T wave changes or left bundle branch block on 12-lead ECG.
- (3) Development of pathological Q waves on ECG.
- (4) Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
- (5) Intracoronary thrombus detected on angiography

The ESC definition of NSTEMI is:

Of those with Universal defined acute myocardial infarction, patients with acute chest pain, but no persistent ST-segment elevation. ECG changes may include transient ST-segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves or pseudo-normalization of T waves or the ECG may be normal.

The definition of Type 1 myocardial infarction is:

Atherosclerotic plaque rupture, ulceration, fissure, erosion, or dissection with resulting intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and/or distal embolization and subsequent myocardial necrosis. The patient may have underlying severe coronary artery disease but, on occasion, there may be non-obstructive coronary atherosclerosis or no angiographic evidence of coronary artery disease.




Figure 1 The EURObservational Research Programme participating countries and their colour-coded contribution. EORP, EURObservational Research Programme.




Figure 2 Centre distribution per country and number of patients included per centre.

information concerning the study and signed informed consent. Patients <18 years and those unwilling or unable to give consent were not included.

In total, 3620 patients were enrolled from 287 centres in 59 countries (Figures 1 and 2). Of 2947 patients that formed the analytical cohort (excluding patients who did not meet the period inclusion criteria, had inadequate data completeness or other exclusions) 30.8%

were women, 79.3% Caucasian, and the median age was 66 years (interquartile range 57 to 75 years).

Patient identification

Potential participants were identified from admission to hospitals managing patients with NSTEMI and each patient was given a unique study number.

Start points

During the study (and centre) enrolment period, consecutive patients aged ≥ 18 years, hospitalised with a final diagnosis of NSTEMI were included, in whom type 1 myocardial infarction was confirmed.

Baseline and follow-up data

Baseline data included the enrolment setting, patient demographics, cardiovascular risk factors, mode of admission, therapeutic methods, time delays to reperfusion, risk stratification, adverse events, and medications during admission and at discharge. Quality of care was evaluated based on guideline-recommended NSTEMI care interventions including electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. Follow-up for clinical events and life status was recorded at 30 days.

Data capture and storage

Data were manually entered by investigators or data collecting officers at the participating centres in the registry-specific online eCRF that is accessible using the individual's unique username and password distributed by the EORP team. Collected patient data are pseudonymous and only a unique code identifies a patient in the EORP database. Pseudonymized data are stored in the registry-specific central database with limited access protected by individual passwords. The EORP NSTEMI Registry database is stored at the EORP Department, European Heart House, 2035 route des Colles, 06 903 Sophia Antipolis, France.

Data quality

The EORP NSTEMI registry database is designed, managed, controlled, and validated according to the ESC EORP standards. The EORP NSTEMI eCRF has numerous built-in automatic cross-checks for data completeness, internal consistency, and validity that automatically raises alerts in case of data incompleteness or inconsistency, thus enabling investigators to resolve such issues during data entry. In addition, data were regularly assessed and validated by the EORP-NSTEMI Data Management Team, according to the Data Validation Plan, no formal source data verification was undertaken.

Endpoints and linkage to other data

Adherence to guidelines during the inpatient stay and subsequent 30-day all-cause mortality will be investigated. Secondary outcomes include in-hospital episodes of acute heart failure, cardiogenic shock, use of mechanical circulatory support, bleed (BARC Type ≥ 3),¹⁹ stroke/transient ischaemic attack, and recurrent myocardial infarction. These endpoints will be directly entered in the eCRF, as reported by the participating investigators and supported by pertinent medical records. It is anticipated that the EORP NSTEMI registry could provide a legacy platform for future NSTEMI data capture.

Access to data

Direct access to the Registry dataset is limited to the EORP NSTEMI Data Management and Statistical Analysis teams. Country-specific datasets may be provided to the national cardiology societies/national coordinators for subsequent analysis of the country-specific data.

Conclusions

The EORP NSTEMI Registry is an international, prospective registry of care for and outcomes of patients treated for NSTEMI across a wide sample of ESC and ESC-affiliated countries. This registry will provide insights into the patterns of NSTEMI management, implementation of ESC 2015 NSTEMI guidelines in routine practice, and potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality. Data will be reported as research publications and health reports to the wider ESC community, and provide the opportunity for interventions to increase guideline implementation in practice.

Acknowledgment

The EORP Oversight Committee, Registry Executive, and Steering Committees. The project management (study launch, data collection coordination, data management, and statistical analyses) was conducted by the EURObservational Research Programme (EORP), European Society of Cardiology (ESC), Sophia-Antipolis, France: Catherine Bosc and Carole Toulouse as Clinical Project Managers, Sylvie Chanoni and Emanuela Fiorucci as Project Officers; Gagan Chhabra and Sandrine Anglars as Data Managers, Cécile Laroche as Statistical Project Lead. Overall activities were coordinated and supervised by Doctor Aldo P. Maggioni (EORP Scientific Coordinator). Special thanks to the Acute Cardiovascular Care Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Funding

Since the start of EORP, the following companies have supported the programme: Abbott Vascular Inc. (2011–20), Amgen Cardiovascular (2009–18), AstraZeneca (2014–21), Bayer AG (2009–18), Boehringer Ingelheim (2009–19), Boston Scientific (2009–12), Bristol Myers Squibb and Pfizer Alliance (2011–19), Daiichi Sankyo Europe GmbH (2011–20), the Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–17), Edwards (2016–19), Gedeon Richter Plc. (2014–16), Menarini Int. Op. (2009–12), MSD-Merck & Co. (2011–14), Novartis Pharma AG (2014–20), ResMed (2014–16), Sanofi (2009–11), Servier (2009–21), and Vifor (2019–22).

Declaration of Helsinki

The study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects (or their legally authorized representative).

Data availability

The data underlying this article are subject to an embargo of 12 months from the publication date of the article. Once the embargo expires, the data will be available upon reasonable request to the EORP NSTEMI Executive Committee Chair, with the approval of the EORP Oversight Committee.

Conflict of interest: H.B., K.H., M.L., P.L., R.N., V.K., and Y.A. report no conflict of interest.

C.P.G. reports personal fees from AstraZeneca, Amgen, Bayer, Boehringer-Ingelheim, Daiichi Sankyo, Vifor Pharma, Menarini, Wondr Medical, Raisio Group, and Oxford University Press. He has received educational and research grants from BMS, Abbott inc., the British Heart Foundation, National Institute of Health Research, Horizon 2020, and the European Society of Cardiology, outside the submitted work.

S.B. reports personal fees from Boston Scientific, Insight, Lifetech, Vascular, and Abbott Vascular.

D.M. reports personal fees from Abbott, Boston Scientific, Biosensors, and Terumo. He has participated in Data Safety Monitoring Boards or Advisory Boards for Abbott, and Boston Scientific.

A.B. reports personal and institutional investigator fees from AstraZeneca, Bristol Myers Squibb/Pfizer, Sanofi Aventis, Eisai, Novartis, GlaxoSmithKline, Amgen, Novo Nordisk, and Bayer. He reports personal fees from AstraZeneca, Bristol Myers Squibb/Pfizer, Sanofi Aventis, GlaxoSmithKline, Novartis, and Bayer. He has participated in Data Safety Monitoring Boards or Advisory Boards for AstraZeneca, Bristol Myers Squibb/Pfizer, Sanofi Aventis, GlaxoSmithKline, and Bayer. He has received support for attending meetings by AstraZeneca, Bristol Myers Squibb/Pfizer, Sanofi Aventis, and Bayer.

S.L. reports personal fees from ICON, Chiesi, AstraZeneca, Daiichi Sankyo, Bayer, Bristol Myers Squibb/Pfizer, and Novo Nordisk.

M.L. reports personal fees from Bristol Myers Squibb, Pfizer, Boehringer-Ingelheim, Sanofi, Edwards Lifesciences. She has also been an advisory board member for Bristol Myers Squibb, Sanofi and Boehringer-Ingelheim.

Signed COIs available for all authors.

Appendix 1

EORP Oversight Committee

2016-2018: A. Vahanian, FR (Chair); A. Budaj, PL; N. Dagnes, DE; N. Danchin, FR; V. Delgado, NL; J. Emberson, GB; O. Friberg, SE; C.P. Gale, GB; G. Heyndrickx, BE; B. Lung, FR; S. James, SE; A.P. Kappetein, NL; A.P. Maggioni, IT; N. Maniadas, GR; K.V. Nagy, HU; G. Parati, IT; A.S. Petronio, IT; M. Pietila, FI; E. Prescott, DK; F. Ruschitzka, CH; F. Van de Werf, BE; F. Weidinger, AT; U. Zeymer, DE. **2018-2020:** C.P. Gale, GB (Chair); B. Beleslin, RS; A. Budaj, PL; O. Chioncel, RO; N. Dagnes, DE; N. Danchin, FR; J. Emberson, GB; D. Erlinge, SE; M. Glikson, IL; A. Gray, GB; M. Kayikcioglu, TR; A.P. Maggioni, IT; K.V. Nagy, HU; A. Nedoshivin, RU; A.P. Petronio, IT; J.W. Roos-Hesselink, NL; L. Wallentin, SE; U. Zeymer, DE. **2020-2022:** B.A. Popescu, RO (Chair); D. Adlam, GB; A.L.P. Caforio, IT; D. Capodanno, IT; M. Dweck, GB; D. Erlinge, SE; M. Glikson, IL; J. Hausleiter, DE; B. Lung, FR; M. Kayikcioglu, TR; P. Ludman, GB; L. Lund, SE; A.P. Maggioni, IT; S. Matskeplishvili, RU; B. Meder, DE; K.V. Nagy, HU; A. Nedoshivin, RU; D. Neglia, IT; A.A. Pasquet, BE; J.W. Roos-Hesselink, NL; F.J. Rossello, ES; S.M. Shaheen, EG; A. Torbica, IT.

Executive Committee

Christopher Peter Gale (Chair), Peter F Ludman (Chair), Maddalena Lettino, Hector Bueno, Kurt Huber, Sergio Leonardi, Andrzej Budaj, Dejan Milasinovic (Serbia), Salvatore Brugaletta, Yolande Appelman, Vijay Kunadian

National Coordinators

AE: Wael Abdul Rahman Al Mahmeed, AM: Hovhannes Kzhdryan, AR: Carlos Dumont, AT: Alexander Geppert, BA: Nirvana Sabanovic Bajramovic, BD: Fathima Aaysha Cader, BE: Christophe Beauloye, CR: Daniel Quesada, CZ: Ota Hlinomaz, DE: Christoph Liebetrau, EE: Toomas Marandi, EG: Khaled Shokry, ES: Héctor Bueno, FR: Jacques Mansourati, GB: Chris P Gale, GE: David Maisuradze, GR: Theodoros Sinanis, ID: Surya Dharma, IL: Katia Orvin, IN: Ajay Sinha, IQ: Hasan Ali Farhan, IR: Parham Sadeghipour, IS: Ingibjorg Gudmundsdottir, IT: Ciro Indolfi, JP: Takeshi Kitai, KG: Erkin Mirrakhimov, LT: Olivija Gustiene, LU: François Philippe, LV: Andrejs Erglis, MD: Mihail Popovici, MK: Oliver Kalpak, MN: Mungunchimeg Dagva, MT: Robert George Xuereb, MY: Wan Azman Wan Ahmad, NL: Yolande Appelman, OM: Sunil K. Nadar, PK: Nadeem Qamar, PL: Marek Gierlotka, PT: Silvia Monteiro, RO: Gheorghe-Andrei Dan, RS: Mina Radovanovic, RU: Elena Vladimirovna Reznik, SA: Mohammed Balghith, SD: Awad Mohamed, SI: Miha Cercek, SK: Denisa Brozmannová, TR: Vedat Aytakin, UG: Prossie Ingabire, UZ: Baxrom Alyavi.

Investigators

Argentina: *La Plata:* L. Cartasegna, V. Nomberto Gomez, C. Beltrano, V. Novas, *Rosario:* C. Dumont, H. Balparda, M. Cardona, C. Cigalini, V. Hoyle, *Rosario:* E. San Dámaso, V. Tapia, **Armenia:** *Yerevan:* K. Poghosyan, S. Mkhitaryan, M. Adamyany, S. Boyadjian, *Yerevan:* H. Hayrapetyan, K. Azaryan, M. Tadevosyan, H. Poghosyan, *Yerevan:* H. Kzhdryan, A. Vardanyan, **Austria:** *Vienna:* K. Huber, A. Geppert, A. Ahmed, *Vienna:* F. Weidinger, M. Derntl, M. Hasun, T. Schuh-Eiring, L. Riegler, **Bangladesh:** *Dhaka:* M.M. Haq, F.A. Cader, M.A.M. Dewan, M-E. Fatema, A.S. Hasan, M.M. Islam, F. Khandoker, R. Mayedah, S.U. Nizam, *Dhaka:* M.G. Azam, M.M. Arefin, J. Jahan, **Belgium:** *Aals:* D. Schelfaut, H. De Raedt, S. Wouters, S. Aerts, H. Batjoens, *Brussels:* C. Beauloye, M. Dechamps, S. Pierard, O. Van Caenegem, F. Sinnaeve, *Edegem:* M.J. Claeys, M. Snepvangers, V. Somers, *Gent:* S. Gevaert, H. Schaubroek, P. Vervae, M. Buysse, *Kortrijk:* F. Renders, M. Dumoulein, N. Hiltrop, M. De Coninck, S. Naessens, I. Senesael, *Liege:* E. Hoffer, S. Pourbaix, J. Beckers, C. Dugauquier, S. Jacquet, D. Malmendier, M. Massoz, *Liege:* P. Evrard, L. Collard, *Mons:* P. Brunner, S. Carlier, M. Blockmans, D. Mayne, E. Timiras, *Yvoir:* A. Guédès, F. Demeure, C. Hanet, J. Domange, K. Jourdan, **Bosnia and Herzegovina:** *Sarajevo:* E. Begic, F. Custovic, A. Dozic, E. Hrvat, I. Kurbasic, D. Mackic, A. Subo, *Sarajevo:* A. Durak-Nalbantic, A. Dzibur, D. Rebic, A. Hamzic-Mehmedbasic, A. Redzepovic, A. Djokic-Vejzovic, E. Hodzic, M. Hujdur, E. Musija, Z. Gljiva-Gogic, N. Serdarevic, *Sarajevo:* N. Sabanovic Bajramovic, L. Brigic, M. Halilcevic, M. Cibo, N. Hadžibegic, N. Kukavica, *Sarajevo:* A. Begic, A. Iglica, A. Osmanagic, N. Resic, M. Vucijak Grgurevic, F. Zvizdic, *Zenica:* B. Pojskic, E. Mujaric, H. Selimovic, M. Ejubovic, L. Pojskic, E. Stimjanin, M. Sut, **Colombia:** *Medellin:* P. Sanchez Zapata, C. Gallego Munoz, L.A. Fajardo Andrade, M.P. Tobon Upegui, L.E. Perez, **Costa Rica:** *Heredia:* J. Chavarria, D. Quesada, K. Alvarado, **Croatia:** *Rijeka:* L. Zaputovic, V. Tomulic, D. Gobic, T. Jakljevic, D. Lulic, G. Bacic, L. Bastiancic, **Cyprus:** *Nicosia:* P. Avraamides, C. Eftychiou, N. Eteocleous, A. Ioannou, C. Lambrianidi, M. Drakomathoulakis, **Czech Republic:** *Brno:* L. Groch, O. Hlinomaz, M. Rezek, J. Semenka, J. Sitar, M. Beranova, P. Kramarikova, *Ceske Budejovice:* L. Pesi, S. Sindelarova, F. Tousek, **Egypt:** *Alexandria:* H.M. Warda, I. Ghaly, S. Habiba, A. Habib, *Aswan:* M.N. Gergis, H. Bahaa, A. Samir, *Cairo:* H. Salah Eldin Taha, M. Adel, H. Mahrous Algamal, M. Mamdouh, *Cairo:* A. Foad Shaker, K. Shokry, A. Konsoah, A. Magdy Mostafa, A. Ibrahim, *Cairo:* A. Imam, B. Hafez, A. Zahran, *Cairo:* M. Abdelhamid, K. Mahmoud, A. Mostafa, A. Samir, M. Abdrabou, A. Kamal, S. Sallam, *Minya:* A. Ali, K. Maghraby, A. Radi Atta, *Zagazig:* A. Saad, M. Ali, **Estonia:** *Tallinn:* E-M. Lotman, R. Lubi, H. Kaljumäe, *Tallinn:* T. Uuetoa, U. Kiitam, **France:** *Argenteuil:* C. Durier, *Auxerre:* O. Ressencourt, A. Alaa El Din, A. Guiatni, M. Le Bras, E. Mougnot, *Bayonne:* J-N. Labeque, J-L. Banos, O. Capendeguy, *Brest:* J. Mansourati, A. Fofana, M. Augagneur, L. Bahon, A. Le Pape, *Chambery:* L. Batias-Moreau, A. Fluttaz, F. Good, F. Prieur, *La Roche-Sur-Yon:* E. Boiffard, A-S. Derien, I. Drapeau, N. Roy, *Lyon:* T. Perret, O. Dubreuil, S. Ranc, S. Rio, *Marseille:* J-L. Bonnet, G. Bonnet, T. Cuisset, P. Deharo, J-P. Mouret, J-C. Spychaj, A. Blondelon, *Pau:* N. Delarche, *Pontoise:* V. Decalf, N. Guillard, A. Hakme, M-P. Roger, *Rennes:* Y. Biron, P. Druelles, C. Loubeyre, A. Lucon, P. Hery, *Saint Denis:* M. Nejari, F. Digne, *Saint Nazaire:* F. Huchet, *Thonon-Les-Bains:* A. Neykova, B. Tzvetkov, M. Larrieu, *Toulon:* G. Quaino, P. Armangau, *Toulouse:* A. Sauguet, L. Bonfils, N. Dumonteil, J. Fajadet, B. Farah, B. Honton, B. Monteil, R. Philippart, D. Tchetche, M. Cottin, F. Petit, A. Piquart, *Vandoeuvre-Les-Nancy:* B. Popovic, J. Varlot, **Georgia:** *Tbilisi:* D. Maisuradze, E. Sagirashvili, *Tbilisi:* Z. Kereselidze, L. Totladze, G. Ginturi, D. Lagvilava, **Germany:** *Bad Nauheim:* C. Hamm, C. Liebetrau, M. Haas, C. Hamm, T. Koerschgen, M. Weferling, J-S. Wolter, K. Maier, *Bonn:* G. Nickenig, A. Sedaghat, C. Zachoal, **Greece:** *Athens:* K. Lampropoulos, A. Mpatsouli, A. Sakellaropoulou, K. Tyrovolas, N. Zibounoumi, K. Argyropoulos, F. Toulgaridis, *Athens:* A. Kolyviras, G. Tzanis, V. Tzifos, *Athens:* A. Milkas, S. Papaioannou, K. Kyriazopoulos,

Athens: V. Pylarinou, I. Kontonassakis, C. Kotakos, G. Kourgiannidis, P. Ntoliou, N. Parzakonis, A. Pipertzi, A. Sakalidis, C-L. Ververeli, *Chania*: K. Kafkala, T. Sinanis, G. Diakakis, K. Grammatikopoulos, E. Papoutsaki, T. Patialiatos, M. Mamaloukaki, S.T. Papadaki, Serres: I.E. Kanellos, A. Antoniou, G. Tsinopoulos, C. Goudis, M. Giannadaki, S. Daios, M. Petridou, P. Skantzis, P. Koukis, F. Dimitriadis, M. Savvidis, *Thessaloniki*: I. Styliadis, V. Sachpekidis, A. Pilalidou, N. Stamatiadis, A. Fotoglidis, A. Karakanas, **Hungary**: *Budapest*: Z. Ruzsa, D. Becker, F. Nowotta, **Iceland**: *Reykjavik*: I. Gudmundsdottir, B. Libungan, F. Bjork Skuladottir, H. Halldorsdottir, **India**: *Bangalore*: R. Shetty, S. lyengar, C. Bs, S. G, S. Lakshmana, R. S, *Patna*: N. Tripathy, A. Sinha, B. Choudhary, A. Kumar, A. Kumar, R. Raj, R. Sagar Roy, **Indonesia**: *Jakarta*: S. Dharma, B.B. Siswanto, **Iraq**: *Baghdad*: H. Ali Farhan, I.F. Yaseen, *Baghdad*: M. Al-Zaidi, Z. Dakhil, *Erbil*: S. Amen, B. Rasool, *Najaf*: A. Rajeeb, K. Amber, H. Hameed Ali, *Nasiriyah*: T. Al-Kinani, M. Hashim Almyahi, F. Al-Obaidi, **Islamic Republic of Iran**: *Isfahan*: G. Masoumi, M. Sadeghi, K. Heshmat-Ghahdarjani, H. Roohafza, N. Sarrafzadegan, M. Shafeie, Z. Teimouri-Jervekani, F. Noori, *Tehran*: M. Kyavar, P. Sadeghipour, A. Firouzi, M.J. Alemzadeh-Ansari, B. Ghadroost, R. Golpira, A. Ghorbani, F. Ahangari, *Tehran*: M. Salarifar, Y. Jenab, A. Biria, S. Haghighi, P. Mansouri, S. Yadangi, **Israel**: *Petah-Tikva*: R. Kornowski, K. Orvin, A. Eisen, N. Oginetz, R. Vazel, H. Kfir, **Italy**: *Bologna*: G. Di Pasquale, G. Casella, L.S. Cardelli, E. Filippini, S. Zagnoni, *Bolzano*: L. Donazzan, D. Ermacora, *Catanzaro*: C. Indolfi, A. Polimeni, A. Curcio, A. Mongiardo, S. De Rosa, S. Sorrentino, C. Spaccarotella, *Crema*: M. Landolina, M. Marino, M. Cacucci, L. Vailati, *Genoa*: P. Bernabò, *Monserato*: R. Montisci, L. Meloni, M.F. Marchetti, M. Biddau, E. Garau, *Naples*: E. Barbato, C. Morisco, T. Strisciuglio, G. Canciello, *Nuoro*: G. Lorenzoni, G. Casu, P. Merella, *Palermo*: G. Novo, A. D'Agostino, D. Di Lisi, A. Di Palermo, S. Evola, F. Immordino, L. Rossetto, G. Spica, *Pordenone*: D. Pavan, A. Della Mattia, R. Belfiore, U. Grandis, F. Vendrametto, C. Spagnolo, L. Carniel, E. Sonogo, *Rome*: C. Gaudio, F. Barilla, F.G. Biccire, N. Bruno, I. Ferrari, V. Paravati, C. Torromeo, *Salerno*: G. Galasso, A. Peluso, C. Prota, I. Radano, R.M. Bengenga, D. Ferraioli, *San Bonifacio*: M. Anselmi, G.M. Frigo, *Trieste*: G. Sinagra, M. Merlo, A. Perkan, F. Ramani, A. Altinier, E. Fabris, *Turin*: M. Rinaldi, T. Usmiani, L. Checco, S. Frea, M. Mussida, **Japan**: *Fukuoka*: R. Matsukawa, *Hidaka City*: K. Sugi, *Kobe*: T. Kitai, Y. Furukawa, A. Masumoto, Y. Miyoshi, *Shimotsugagun-Tochigi*: S. Nishino, **Kazakhstan**: *Almaty*: B. Assembekov, B. Amirov, Y. Chernokurova, F. Ibragimova, **Kyrgyzstan**: *Bishkek*: E. Mirrakhimov, A. Ibraimova, T. Murataliev, Z. Radzhapova, E. Sultan Uulu, N. Zhanyshbekova, V. Zventsova, **Latvia**: *Riga*: A. Erglis, L. Bondare, **Lithuania**: *Kaunas*: R. Zaliunas, O. Gustiene, R. Dirsiene, J. Marcinkeviciene, G. Sakalyte, A. Virbickiene, G. Baksyte, L. Bardauskiene, R. Gelmaniene, A. Salkauskaite, G. Ziubryte, *Siauliai*: N. Kupstyte-Kristapone, *Vilnius*: J. Badariene, S. Balciute, L. Kapleriene, M. Lizaitis, J. Marinskiene, A. Navickaite, A. Pilkiene, D. Ramauskaite, R. Serpytis, D. Silinskiene, T. Simbelyte, J. Staigyte, **Luxembourg**: *Luxembourg*: F. Philippe, P. Degrell, E. Camus, **Malaysia**: *Kuala Lumpur*: W.A. Wan Ahmad, Z. Abu Kassim, **Malta**: *Msida*: R.G. Xuereb, L-L. Buttigieg, W. Camilleri, E. Pllaha, S. Xuereb, **Moldova, Republic Of**: *Chisinau*: M. Popovici, V. Ivanov, A. Plugaru, V. Moscalu, I. Popovici, M. Abras, L. Ciobanu, N. Litvinenco, S. Fuior, C. Dumanschi, M. Ivanov, T. Danila, *Chisinau*: L. Grib, S. Filimon, L. Cardaniuc, *Chisinau*: A. Batrinac, M. Tasnic, C. Cozma, V. Revenco, *Chisinau*: G. Sorici, **Mongolia**: *Ulaanbaatar*: M. Dagva, G. Chojiljav, E. Dandar, M-U. Khurelbaatar, B. Tsognemekh, **Netherlands**: *Amsterdam*: Y. Appelman, A. Den Hartog, H. Jan Te Kolste, D. Van Den Buijs, *Heerlen*: A. Van'T Hof, T. Pustjens, V. Houben, I. Kasperski, *Nieuwegein*: J. Ten Berg, J. Azzahhafi, W. Bor, D. Chan Pin Yin, **Nigeria**: *Lagos*: A. Mbakwem, C. Amadi, O. Kushimo, M. Kilasho, E. Oronsaye, **North Macedonia**: *Ohrid*: N. Bakracheski, E. Kovacheska Bashuroska, V. Mojsovska, S. Tupare, M. Dejan, J. Jovanoska, D. Razmoski, T. Marinovski, *Skopje*: A. Antovski, Z. Jovanovski, S. Kocho, R. Markovski, V. Ristovski, A.B. Samir, S. Biserka, *Skopje*: O. Kalpak, I. Mitevska Peovska, B. Zafirovska Taleska, H. Pejkov, O. Busljetik, Z. Zimbakov, E. Grueva, I. Bojovski, M. Tutic, *Skopje*: L. Poposka, M. Vavlukis, **Oman**: *Muscat*: A. Al-Riyami, S.K. Nadar, W. Abdelmottaleb, S. Ahmed, M. Shaikh Mujtaba, S. Al-Mashari, H. Al-Riyami, **Pakistan**: *Karachi*: A.H. Laghari, O. Faheem, S. Waqar Ahmed, *Karachi*: N. Qamar, S. Furnaz, K. Kazmi, T. Saghir, A. Aneel, A. Asim, F. Madiha, **Poland**: *Bialystok*: B. Sobkowicz, A. Tycinska, E. Kazimierczyk, A. Szyszkowska, *Katowice*: K. Mizia-Stec, M. Wybraniec, A. Bednarek, K. Glowacki, *Kedzierzyn-Kozle*: J. Prokopczuk, W. Babiniski, A. Blachut, M. Kosiak, A. Kusinska, S. Samborski, J. Stachura, H. Szastok, A. Wester, D. Bartoszewska, *Kielce*: B. Sosnowska-Pasiarska, M. Krzysiek, *Krakow*: J. Legutko, B. Nawrotek, *Lodz*: J.D. Kasprzak, M. Klosinska, K. Wiklo, *Lodz*: M. Kurpesa, T. Rechcinski, U. Cieslik-Guerra, *Opole*: M. Gierlotka, J. Bugajski, P. Feusette, J. Sacha, P. Przybylo, *Warsaw*: P. Krzesinski, R. Ryzek, A. Karasek, A. Kazmierczak-Dziuk, M. Mielniczuk, K. Betkier-Lipinska, *Warsaw*: M. Roik, A. Labyk, M. Krakowian, M. Machowski, M. Paczynska, M. Potepa, P. Pruszczuk, *Warsaw*: A. Budaj, M. Ambroziak, E. Omelanczuk-Wiech, A. Torun, *Warsaw*: G. Opolski, R. Glowczynska, A. Fojt, R. Kowalik, *Warsaw*: Z. Huczek, S. Jedrzejczyk, *Wroclaw*: T. Roleder, K. Bost, *Zabrze*: M. Gasior, P. Desperak, M. Hawranek, **Portugal**: *Amadora*: P. Farto-Abreu, M. Santos, S. Baptista, L. Brizida, D. Faria, J. Loureiro, P. Magno, C. Monteiro, M. Nédio, *Barreiro*: J. Tavares, C. Sousa, I. Almeida, S. Almeida, H. Miranda, H. Santos, A.P. Santos, *Coimbra*: L. Goncalves, S. Monteiro, R. Baptista, C. Ferreira, J. Ferreira, F. Goncalves, C. Lourenço, P. Monteiro, *Evora*: B. Picarra, A.R. Santos, R. Azevedo Guerreiro, M. Carias, M. Carrington, J. Pais, M. Paralta de Figueiredo, A.R. Rocha, *Faro*: J. Mimoso, I. De Jesus, R. Fernandes, J. Guedes, T. Mota, *Lisbon*: M. Mendes, J. Ferreira, A. Tralhão, C. Tavares Aguiar, C. Strong, F. Fernandes Da Gama, G. Pais, *Lisbon*: A.T. Timóteo, S. Aguiar Oliveira Rosa, T. Mano, J. Reis, M. Selas, *Loures*: D. Espregueira Mendes, M. Satendra, *Penafiel*: P. Pinto, C. Queirós, I. Oliveira, L. Reis, I. Cruz, R. Fernandes, *Porto*: S. Torres, A. Luz, A. Campinas, R. Costa, A. Frias, M. Oliveira, *Santarem*: V. Martins, B. Castilho, C. Coelho, A.R. Moura, N. Cotrim, *Vila Franca de Xira*: R. Carvalheira Dos Santos, P. Custodio, R. Duarte, R. Gomes, F. Matias, C. Mendonca, J. Neiva, C. Rabacal, A. Rocha Almeida, *Vila Nova de Gaia*: D. Caeiro, P. Queiroz, G. Silva, **Romania**: *Arad*: A.L. Pop-Moldovan, D. Darabantiu, S. Mercea, *Bucharest*: G-A. Dan, A-R. Dan, M. Dobranici, R.A. Popescu, C. Adam, *Bucharest*: C-J. Sinescu, C-L. Andrei, R. Brezeanu, N. Samoila, *Bucharest*: M.M. Baluta, *Cluj-Napoca*: D. Pop, R. Tomoiaia, *Craiova*: O. Istratoaie, I. Donoiu, A. Cojocar, O.C. Oprita, A. Rocsoreanu, *Iasi*: M. Grecu, S. Ailoeai, *Oradea*: M. Ioachim Popescu, A. Cozma, E. Emilia Babes, M. Rus, A. Ardelean, R. Larisa, M. Moisi, E. Ban, A. Buzle, G. Filimon, *Targu-Mures*: D. Dobreanu, S. Lupu, A. Mitre, R. Rudzik, I. Sus, D. Opris, C. Somkereki, *Timisoara*: C. Mornos, L. Petrescu, A. Betiu, A. Volcescu, O. Ioan, C. Luca, D. Maximov, S. Mosteoru, L. Pascalau, C. Roman, D. Brie, S. Crisan, C. Erimescu, L. Falnita, D. Gaita, M. Gheorghiu, **Russian Federation**: *Chelyabinsk*: S. Levashov, M. Redkina, *Kaluga*: N. Novitskii, E. Dementiev, A. Baglikov, *Moscow*: D. Zateyshchikov, E. Zubova, A. Rogozhina, *Moscow*: A. Salikov, I. Nikitin, E.V. Reznik, M.S. Komissarova, M. Shebzukhova, K. Shitaya, S. Stolbova, *Moscow*: V. Larina, F. Akhmatova, G. Chuvarayan, *Moscow*: M.N. Arefyev, O.V. Averkov, A.L. Volkova, M.S. Sepkhanian, V.I. Vecherko, *Moscow*: I. Meray, L. Babaeva, L. Goreva, A. Pisaryuk, P. Potapov, M. Teterina, *Moscow*: F. Ageev, G. Silvestrova, *Moscow*: Y. Fedulaev, T. Pinchuk, *Moscow*: I. Staroverov, D. Kalimullin, T. Sukhinina, N. Zhukova, *Tomsk*: V. Ryabov, E. Kruchinkina, D. Vorobeva, *Voronezh*: I. Shevchenko, V. Budyak, O. Elistratova, E. Fetisova, R. Islamov, E. Ponomareva, **Saudi Arabia**: *Hail*: H. Khalaf, A. Al Shaimaa, W. Kamal, *Jeddah*: J. Arahimi, A. Elshiekh, *Riyadh*: M. Balghith, A. Ahmed, N. Attia, A.A. Jamiel, **Serbia**: *Belgrade*: T. Potpara, M. Marinkovic, M. Mihajlovic, N. Mujovic, A. Kocijancic, Z. Mijatovic, *Belgrade*: M. Radovanovic, D. Matic, A. Milosevic, L. Savic, I. Subotic, A. Uscumlic, N. Zlatic, J. Antonijevic, O. Vesic, *Kragujevac*: R. Vucic, *Nis*: S. Salinger Martinovic,

T. Kostic, V. Atanaskovic, V. Mitic, D. Stanojevic, **Sremaska Kamenica**: M. Petrovic, M. Kovacevic, B. Crnomarkovic, M. Cankovic, D. Dabovic, M. Jarakovic, T. Pantic, M. Trajkovic, L. Pupic, **Valjevo**: D. Ruzicic, D. Cvetanovic, I. Obradovic, M. Stankovic, **Singapore**: Singapore: P.H. Loh, W. Kong, K-K. Poh, C-H. Sia, K. Saw, **Slovakia**: Bratislava: D. Liška, D. Brozmannová, **Kosice**: M. Gbur, R. Maxian, **Slovenia**: Celje: D. Kovacic, N. Glavnik Poznic, T. Keric, G. Kotnik, **Ljubljana**: M. Cercek, K. Steblovnik, M. Sustersic, A. Cerne Cercek, I. Djokic, B. Drnovsek, L. Lipar, M. Mocilnik, A. Pleskovic, **Murska Sobota**: M. Lainscak, D. Crncic, I. Nikojajevic, M. Tibaut, M. Cigut, **Trbovlje**: B. Leskovar, T. Furlan, V. Grilj, M. Rezun, **Spain**: *Alcazar de San Juan*: V. Martinez Mateo, M.J. Fernandez Anguita, *Aviles*: I.C. Möller Bustinza, R. Bangueses Quintana, O.C. Fernandez Cimadevilla, J. Fuertes, F. Lopez, M.D. Martin, L. Martinez, *Barcelona*: J.A. Barrabes, J. Bañeras, Y. Belahnech, I. Ferreira-Gonzalez, P. Jordan, R-M. Lidon, L. Mila, A. Sambola, *Barcelona*: A. Sionis, W. Bragagnini, A. Duran Cambra, C. Simon, M. Vidal Burdeus, *Barcelona*: A. Ariza-Solé, O. Alegre, M. Alsina, J.J. Llaó Ferrando, *Barcelona*: X. Bosch, P. Vidal, M. Izquierdo, *El Palmar*: F. Marin, M.A. Esteve-Pastor, A. Tello-Montoliu, C. Lopez-Garcia, J.M. Rivera-Caravaca, P. Gil-Pérez, *Lorca*: S. Nicolas-Franco, I. Keituqwa, *Madrid*: L. Silva, A. Blasco, J.M. Escudier, J. Ortega, *Madrid*: J.L. Zamorano, M. Sanmartin, D. Cordero Pereda, L.M. Rincon, P. Gonzalez, T. Casado, *Madrid*: J.L. Lopez-Sendon, A.M. Iniesta Manjavacas, L.A. Martinez Marin, L. Rodriguez Sotelo, S.O. Rosillo Rodriguez, *Madrid*: H. Bueno, R. Martin, R. Maruri, G. Moreno, *Oviedo*: C. Moris, P. Avanzas, A. Ayesta, A. Junco-Vicente, H. Cubero-Gallego, I. Pascual, *Pamplona*: N. Basterra Sola, O. Alcalde Rodriguez, L. Malagon, J. Martinez-Basterra, A. Munarriz Arizcuren, J. Romero, A. Gainza Calleja, *Puertollano*: D. García Fuertes, M. Crespin Crespin, F.J. Castillo Bernal, *San Cristobal de La Laguna, Islas Canarias*: F. Bosa Ojeda, A. Lara Padron, M. Martin Cabeza, C. Mendez Vargas, G. Yanes, M.J. Garcia Gonzalez, J. Gonzalez Gonzalez, P. Jorge, B. De La Fuente, *Sant Joan Despi*: M. Garcia Bermúdez, C.M. Bianchi Perez-Lopez, A. Bonet Basiero, A. Carol Ruiz, R. Freixa Pamias, P. Sanchez Chamero, *Sevilla*: R. Hidalgo-Urbano, J.C. Garcia-Rubira, T. Seoane-Garcia, D.F. Arroyo-Monino, *Tarragona*: A. Bardaji Ruiz, E. Sanz-Girgas, G. Bonet, J. Rodríguez-López, C. Scardino, D. De Sousa, **Sudan**: *Khartoum*: E. Elbasheer, A. Humida, H. Mahmoud, *Khartoum*: A. Mohamed, E. Hamid, S. Hussein, *Khartoum*: M. Abdelhameed, T. Ali, Y. Ali, M. Eltayeb, *Medani*: M. Ali, E. Almubarak, *Omdurman*: M. Badri, S. Altaher, M. Dafa Alla, **Sweden**: *Goteborg*: M. Dellborg, H. Dellborg, G. Hulstberg-Olsson, **Syrian Arab Republic**: *Damascus*: Y. Bani Marjeh, A. Abdin, F. Alhussein, F. Mgazeel, **Tunisia**: *Sfax*: R. Hammami, L. Abid, A. Bahloul, S. Charfeddine, T. Ellouze, **Turkey**: *Ankara*: U. Canpolat, M. Oksul, *Ankara*: H. Muderrisoglu, E. Karacaglar, A. Akgun, *Bursa*: H. Ari, S. Ari, V. Can, B. Tuncay, *Diyarbakir*: H. Kaya, L. Dursun, *Elazig*: K. Kalenderoglu, O. Tasar, *Gaziantep*: S. Kilic, M. Kucukosmanoglu, *Istanbul*: V. Aytekin, O. Baydar, Y. Demirci, E. Gürsoy, A. Kilic, Ö. Yıldiz, *Istanbul*: A. Arat-Ozkan, U.Y. Sinan, *Istanbul*: B. Gungor, S. Sert Sekerci, G. Zeren, *Istanbul*: M. Erturk, A.R. Demir, C. Yildirim, C. Can, *Izmir*: M. Kaykicioglu, B. Yagmur, S. Oney, *Kirikkale*: C. Sabanoglu, I.H. Inanc, *Konya*: M. Ziyrek, *Kutahya*: T. Sen, M.A. Astarcioglu, F. Kahraman, O. Utku, *Mersin*: A. Celik, A.O. Surmeli, *Mugla*: O. Basaran, *Sanliurfa*: R. Demirbag, F. Besli, F. Gungoren, **Uganda**: *Kampala*: P. Ingabire, C. Mondo, S. Ssemanda, T. Semu, **United Arab Emirates**: *Abu Dhabi*: A. Al Mulla, J.S. Atos, I. Wajid, *Abu Dhabi*: W.A.R. Al Mahmeed, B. Atallah, K. Bakr, R. Garrod, F. Makia, *Dubai*: F. Eldeeb, R. Abdekader, A. Gomaa, S. Kandasamy, R. Maruthanayagam, G. Nakad, R. Nair, **United Kingdom**: *Ashford*: P. Mota, P. Prior, S. Mcdonald, J. Rand, N. Schumacher, *Ashton Under Lyne*: A. Abraheem, M. Clark, M. Coulding, V. Turner, *Barnsley*: A.Q. Negahban, A. Crew, S. Hope, J. Howson, S. Jones, N. Lancaster, A. Nicholson, G. Wray, *Belfast*: P. Donnelly, L. Hammond, S. Hammond, S. Regan, *Birmingham*: R. Watkin, C. Papadopoulos, *Birmingham*: P. Ludman, K. Hutton, S. Macdonald, A. Nilsson, S. Roberts, *Blackburn*: S. Garg, K. Balachandran, J. Mcdonald, R. Singh, K. Marsden, K. Davies, H. Desai, W. Goddard,

N. Iqbal, *Blackpool*: S. Chalil, G. Galasko, O. Assaf, L. Benham, J. Brown, S. Collins, C. Fleming, J. Glen, M. Mitchell, S. Preston, A. Uttley, *Bradford*: S. Lindsay, N. Akhtar, C. Atkinson, M. Vinod, A. Wilson, *Buckinghamshire*: P. Clifford, S. Firoozan, M. Yashoman, N. Bowers, J. Chaplin, S. Harvey, M. Kononen, G. Lopesdesousa, F. Saraiva, *Chertsey, Surrey*: S. Sharma, E. Cruddas, J. Law, E. Young, *Cottingham*: A. Hoye, P. Harper, K. Rowe, *Coventry*: M. Been, H. Cummins, E. French, C. Gibson, *Durham*: J.A. Abraham, S. Hobson, A. Kay, M. Kent, A. Wilkinson, S. Clark, L. Duncan, *Fulwood*: I.M. Ahmed, D. Khatiwada, A. Mccarrick, I. Wanda, *Ipswich*: P. Read, A. Afsar, V. Rivers, T. Theobald, S. Bell, C. Buckman, R. Francis, G. Peters, *Liverpool*: R. Stables, M. Morgan, M. Noorzadeh, B. Taylor, S. Twiss, P. Widdows, V. Wilkinson, M. Black, A. Clark, N. Clarkson, J. Currie, L. George, C. Mcgee, *Llanelli*: L. Izzat, T. Lewis, Z. Omar, S. Phillips, *Manchester*: F. Ahmed, S. Mackie, A. Oommen, H. Phillips, M. Sherwood, S. Aleti, T. Charles, M. Jose, L. Kolakaluri, *Margate*: R. Al Karoudi, J. Deery, T. Hazelton, A. Knight, C. Price, S. Turney, *Milton Keynes*: A. Kardos, F. Williams, L. Wren, G. Bega, D. Scaletta, *Newcastle Upon Tyne*: V. Kunadian, K. Cullen, S. Jones, E. Kirkup, *North Shields*: D.P. Ripley, I.G. Matthews, A. Mcleod, C. Runnett, H.E. Thomas, *Nottingham*: A. Gunarathne, J. Burton, R. King, J. Quinn, *Oldham, Greater Manchester, Lancs*: J. Sobolewska, S. Munt, *Peterborough*: J. Porter, V. Christenssen, K. Leng, T. Peachey, N. Temple, K. Wells, *Plymouth*: G. Viswanathan, A. Taneja, E. Cann, C. Eglinton, B. Hyams, E. Jones, F. Reed, J. Smith, D-C. Affleck, A. Turner, T. Ward, N. Wilmshurst, *Reading*: J. Stirrup, M. Brunton, A. Whyte, *Rotherham*: S. Smith, V. Murray, R. Walker, C. Weston, C. Brown, D. Collier, K. Curtis, K. Dixon, *Salisbury*: T. Wells, F. Trim, *Scarborough, East Yorkshire*: J. Ghosh, M. Mavuri, L. Barman, K. Elliott, R. Harrison, J. Mallinson, T. Neale, J. Smith, J. Toohie, A. Turnbull, *Scunthorpe*: E. Parker, R. Hossain, M. Cheeseman, J. Hill, M. Hood, D. Hutchinson, K. Mellows, C. Pendlebury, *Sheffield*: R.F. Storey, J. Barker, K. Birchall, H. Denney, K. Housley, J. Middle, *Stevenage*: N. Kukreja, S. Gati, P. Kirk, M. Lynch, M. Srinivasan, J. Zyguła, P. Baker, C. Cruz, J. Derigay, K. Lamb, S. Nembhard, A. Price, *Stoke-On-Trent*: M. Mamas, I. Massey, J. Wain, J. Delaney, *Sunderland, Tyne and Wear*: S. Junejo, K. Martin, *Swansea, Wales*: D. Obaid, E. Brinkworth, C. Davies, D. Evans, S. Richards, C. Thomas, M. Williams, *Taunton*: M. Dayer, H. Mills, K. Roberts, F. Goodchild, N. Greig, *Telford*: S. Kundu, D. Donaldson, L. Tonks, M. Beekes, H. Button, F. Hurford, N. Motherwell, J. Summers-Wall, *Torquay*: D. Felmeden, P. Keeling, U. Sheikh, A. Yonis, L. Felmeden, D. Hughes, L. Micklewright, A. Summerhayes, J. Sutton, *Uxbridge*: V. Panoulas, C. Prendergast, P. Rogers, L.N. Barker, *Wakefield*: P. Batin, D. Conway, D. Exley, A. Fletcher, J. Wright, *Westcliff-On-Sea*: T. Nageh, B. Hadebe, S. Kunhunni, E. Mshengu, *Wigan*: V.J. Karthikeyan, H. Hamdan, J. Cooper, C. Dandy, V. Parkinson, P. Paterson, S. Reddington, T. Taylor, C. Tierney, K. Vandesnepscheut Jones, *Yeovil*: A. Broadley, K. Beesley, C. Buckley, C. Hellyer, L. Pippard, T. Pitt-Kerby, *York*: J. Azam, C. Hayes, K. Freshwater, L. Johnson, Y. McGill, H. Redfearn, M. Russell, **Uzbekistan**: *Tashkent*: A. Alyavi, B. Alyavi, J. Uzokov.

References

1. Chung S-C, Sundström J, Gale CP, James S, Deanfield J, Wallentin L et al. Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. *BMJ* 2015;**351**.
2. National Institute for Health and Care Excellence. *NICE support for commissioning for acute coronary syndromes (including myocardial infarction)*. <https://www.nice.org.uk/guidance/qs68>.
3. Polonski L, Gasior M, Gierlotka M, Osadnik T, Kalarus Z, Trusz-Gluza M et al. A comparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: are non-ST myocardial infarctions associated with worse long-term prognoses? *Int J Cardiol* 2011;**152**(1):70–77.
4. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;**124**(1):40–47.

5. Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. *BMJ* 2012;**344**.
6. Smith FG, Brogan RA, Alabas O, Laut KG, Quinn T, Bugiardini R et al. Comparative care and outcomes for acute coronary syndromes in Central and Eastern European Transitional countries: A review of the literature. *Eur Heart J Acute Cardiovasc Care* 2015;**4**(6):537–554.
7. Bueno H, Rossello X, Pocock S, Van de Werf F, Chin CT, Danchin N et al. Regional variations in hospital management and post-discharge mortality in patients with non—ST-segment elevation acute coronary syndrome. *Clin res cardiol* 2018;**107**(9): 836–844.
8. Hall M, Dondo TB, Yan AT, Goodman SG, Bueno H, Chew DP et al. Association of clinical factors and therapeutic strategies with improvements in survival following non—ST-elevation myocardial infarction, 2003-2013. *JAMA* 2016;**316**(10):1073–1082.
9. Rossello X, Medina J, Pocock S, Van de Werf F, Chin CT, Danchin N et al. Assessment of quality indicators for acute myocardial infarction management in 28 countries and use of composite quality indicators for benchmarking. *Eur Heart J Acute Cardiovasc Care* 2020;**9**(8):911–922.
10. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *JAMA* 2007;**297**(2):177–186.
11. Briffa T, Hickling S, Knuiam M, Hobbs M, Hung J, Sanfilippo F et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. *BMJ* 2009; **338**.
12. Peterson ED, Shah BR, Parsons L, Pollack CV, Jr, French WJ, Canto JG et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J* 2008;**156**(6): 1045–1055.
13. Bueno H, Rossello X, Pocock SJ, Van de Werf F, Chin CT, Danchin N et al. In-hospital coronary revascularization rates and post-discharge mortality risk in non—ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol* 2019;**74**(11):1454–1461.
14. Schiele F, Gale CP, Bonnefoy E, Capuano F, Claeys MJ, Danchin N et al. Quality indicators for acute myocardial infarction: a position paper of the Acute Cardiovascular Care Association. *Eur Heart J Acute Cardiovasc Care* 2017;**6**(1):34–59.
15. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Kardiol Pol (Polish Heart Journal)* 2015;**73**(12):1207–1294.
16. Bebb O, Hall M, Fox KA, Dondo TB, Timmis A, Bueno H et al. Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register. *Eur Heart J* 2017;**38**(13): 974–982.
17. Schiele F, Gale CP, Simon T, Fox KA, Bueno H, Lettino M et al. Assessment of quality indicators for acute myocardial infarction in the FAST-MI (French registry of acute ST-elevation or non—ST-elevation myocardial infarction) registries. *Circ Cardiovasc Qual Outcomes* 2017;**10**(6):e003336.
18. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al. Infarction EGoBotJESoCACoCAHAWHFTFftUDoM.Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol* 2018;**72**(18):2231–2264.
19. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation* 2011;**123**(23):2736–2747.